Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients

פריטים דומים

• Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib
  מאת: CHEN, YUH-MIN, et al.
  יצא לאור: (2011)
• Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms
  מאת: Chen, Yuh-Min, et al.
  יצא לאור: (2004)
• Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations
  מאת: WU, WEN-SHUO, et al.
  יצא לאור: (2012)
• Circulating free mitochondrial DNA concentration and its association with erlotinib treatment in patients with adenocarcinoma of the lung
  מאת: HUANG, CHU-YUN, et al.
  יצא לאור: (2014)
• The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment
  מאת: Hung, Hsiu-Ying, et al.
  יצא לאור: (2016)